

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



(02(e))

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :		A1	(11) International Publication Number:	WO 98/32426
A61K 9/36, 9/52, 9/66			(43) International Publication Date:	30 July 1998 (30.07.98)
(21) International Application Number:		PCT/IB97/01646		
(22) International Filing Date:		16 December 1997 (16.12.97)		
(30) Priority Data:		08/790,530	29 January 1997 (29.01.97)	US
(71) Applicant (<i>for all designated States except US</i>): POLIN INDUSTRIA CHIMICA S.P.A. [IT/IT]; Piazza Agrippa, 1, I-20141 Milano (IT).				
(72) Inventors; and				
(75) Inventors/Applicants (<i>for US only</i>): BUSETTI, Cesare [IT/IT]; Via Signorini, 7, I-20149 Milano (IT). CRIMELLA, Tiziano [IT/IT]; Via Londonio, 1, I-20154 Milano (IT).				
(74) Agents: HORNER, Martin, Grenville et al.; Cruikshank & Fairweather, 19 Royal Exchange Square, Glasgow G1 3AE (GB).				
(54) Title: TIME-SPECIFIC CONTROLLED RELEASE DOSAGE FORMULATIONS AND METHOD OF PREPARING SAME				
(57) Abstract				
<p>The present invention provides a method of achieving the time-specific delivery of a pharmaceutically active agent to a patient in need of the therapeutic effects of the pharmaceutically active agent. The method includes administering a pharmaceutical formulation comprising (a) a core including the pharmaceutically active agent to be delivered, and (b) a swellable polymeric coating layer substantially surrounding the core. The swellable polymeric coating layer delays the release of the pharmaceutically active agent from the core for a predetermined period of time dependent upon the thickness of the swellable polymeric coating layer. The swellable polymeric coating layer surrounding the core is provided by a new method which includes alternately (i) wetting the core with a binder solution, and (ii) coating the core with powdered polymeric particles a sufficient number of times to produce a time-specific dosage formulation having the desired thickness of swellable polymeric coating layer.</p>				

Published

With international search report.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5

TIME-SPECIFIC CONTROLLED RELEASE DOSAGE FORMULATIONS AND METHOD OF PREPARING SAME

Related Application

10 The instant application is a continuation-in-part application of U.S. Patent Application Serial No. 08/790,530, filed 29 January 1997, to which a claim of priority is asserted. The subject matter of parent application Serial No. 08/790,530 is incorporated herein by reference in its entirety.

15

Field of the Invention

The present invention relates to controlled release dosage formulations. More particularly, the present invention relates to a method of preparing a time-specific controlled release dosage formulations.

20

Background of the Invention

Pharmaceutical formulations for oral administration have employed various coatings for the purpose of preserving the integrity of the formulation while passing through the gastric tract. The high acidity, and presence of proteolytic and other enzymes generates a highly digestive environment which readily disintegrates pharmaceutical formulations which do not possess some type of gastro-resistance protection.

25

In recent years, a need has arisen for formulations which are capable of passing over the entire tract of the small intestine, including the duodenum, jejunum, and ileum, so that the active ingredients are released directly in the colon. For example, European Patent Application No. 366 621 provides a formulation for delivery in the colon which includes a core containing the active ingredient and three protective layers having differing solubilities around the core. As another example, our European Application No. 572 942, the disclosure of which is hereby incorporated by reference in its entirety, provides an oral pharmaceutical

30

composition including a core containing the active ingredient, an intermediate coating layer which delays the release of the active ingredient contained in the core for a programmed time period, and an outer layer, the dissolution of which activates the process of swelling/dissolution/erosion of the intermediate layer. In the composition described in European Application No. 572 942, the coating layers are applied sequentially by watery or organic film coating or by press coating techniques, such as double press coating. A primary disadvantage of these coating methods is that these methods employ solutions of the coating polymers, which coating polymers have very high viscosities in water-based environments.

Double press coating techniques have some disadvantages in that the core of the formulation may not be properly centered within the coating, and a relatively large amount of polymer is required for proper coating.

There also remains a need in the art for pharmaceutical formulations which release active ingredient after a predetermined latency or lag time period in the body, i.e., time-specific release formulations.

15

Summary of the Invention

It is therefore an object of the present invention to provide a method of preparing a time-specific release pharmaceutical formulation which is faster than conventional coating techniques. It is also an object of the present invention to provide a time-specific pharmaceutical formulation, the disintegration of which is triggered by time lapse, independently of the pH of the environment to which it is subjected.

As a first aspect, the present invention provides a method of achieving the time-specific delivery of a pharmaceutically active agent to a patient in need of the therapeutic effects of the pharmaceutically active agent. The method includes administering a pharmaceutical formulation comprising (a) a core including the pharmaceutically active agent to be delivered, and (b) a swellable polymeric coating layer substantially surrounding the core. The swellable polymeric coating layer delays the release of the pharmaceutically active agent from the core for a predetermined period of time dependent upon the thickness of the swellable polymeric coating layer.

Line 22 29

As a second aspect, the present invention provides a method of providing the swellable polymeric coating layer surrounding the core. The method includes alternately (I)

wetting the core with a binder solution, and (ii) coating the core with powdered polymeric particles a sufficient number of times to produce a time-specific dosage formulation having the desired thickness of swellable polymeric coating layer.

As a third aspect, the present invention provides another method for time-specific delivery of a pharmaceutically active agent to a patient in need of the therapeutic effects of the pharmaceutically active agent. The method comprises administering a pharmaceutical formulation comprising (a) a core including the pharmaceutically active agent, and (b) a swellable polymeric coating layer substantially surrounding the core, that delays the release of the pharmaceutically active agent from the core for a predetermined period of time dependent upon the thickness of the swellable polymeric coating layer. The swellable polymeric coating layer is formed from powdered polymeric particles.

As a fourth aspect, the present invention provides a method for producing a time-specific dosage formulation for the time-specific delivery of a pharmaceutically active agent. The method comprises coating a core containing the pharmaceutically active agent with a swellable polymeric coating layer that delays the release of the pharmaceutically active agent from the core for a predetermined period of time dependent upon the thickness of the swellable polymeric coating layer. The step of coating the core with the swellable polymeric coating layer comprises alternately (I) wetting the core with a binder solution, and (ii) coating the core with powdered polymeric particles a sufficient number of times to produce a time-specific dosage formulation having the desired thickness of swellable polymeric coating layer.

As a fifth aspect, the present invention provides another method for time-specific delivery of a pharmaceutically active agent to a patient in need of the therapeutic effects of the pharmaceutically active agent. The method comprises administering to the patient, a pharmaceutical formulation comprising (a) a core which comprises a capsule containing a liquid form of the pharmaceutically active agent, and (b) a swellable polymeric coating layer substantially surrounding the core. The swellable polymeric coating layer delays the release of the pharmaceutically active agent from the core for a predetermined period of time dependent upon the thickness of the swellable polymeric coating layer. The swellable polymeric coating layer is provided by alternately (I) wetting the core with a binder solution, and (ii) coating the core with powdered polymeric particles a sufficient number of times to

produce a time-specific dosage formulation having the desired thickness of swellable polymeric coating layer.

As a sixth aspect, the present invention provides yet another method for time-specific delivery of a pharmaceutically active agent to a patient in need of the therapeutic effects of the pharmaceutically active agent. The method comprises administering a pharmaceutical formulation comprising: (a) a core which comprises a capsule containing a liquid form of the pharmaceutically active agent, and (b) a swellable polymeric coating layer substantially surrounding the core. The swellable polymeric coating delays the release of the pharmaceutically active agent from the core for a predetermined period of time dependent upon the thickness of the swellable polymeric coating layer. The swellable polymeric coating layer is formed from powdered polymeric particles.

As a seventh aspect, the present invention provides another method for producing a time-specific dosage formulation for time-specific delivery of a pharmaceutically active agent. The method comprises coating a core comprising a capsule containing a liquid form of the pharmaceutically active agent, with a swellable polymeric coating layer that delays the release of the pharmaceutically active agent from the core for a predetermined period of time dependent upon the thickness of the swellable polymeric coating layer. The step of coating the core with the swellable polymeric coating layer comprises alternately (I) wetting the core with a binder solution, and (ii) coating the core with powdered polymeric particles a sufficient number of times to produce a time-specific dosage formulation having the desired thickness of swellable polymeric coating layer. The core can be provided by the steps of (1) providing a liquid form of the pharmaceutically active agent, which form is selected from the group consisting of solutions, liposome dispersions, oil-in-water emulsions, microemulsions, precursors of microemulsions and liposomes, dispersions of microparticles, dispersions of nanoparticles, dispersions of solid lipid nanoparticles, and suspensions, and (2) encapsulating the liquid form of the pharmaceutically active agent in a capsule, prior to coating the core with the swellable polymeric coating layer.

As another aspect, the present invention provides a pharmaceutical formulation for the time-specific delivery of a pharmaceutically active agent. The formulation comprises: (a) a core which comprises a capsule containing a liquid form of the pharmaceutically active agent, and (b) a swellable polymeric coating layer substantially

surrounding the core. The swellable polymeric coating layer delays the release of the pharmaceutically active agent from the core for a predetermined period of time dependent upon the thickness of the swellable polymeric coating layer. The swellable polymeric coating layer is provided by alternately (I) wetting the core with a binder solution, and (ii) coating the 5 core with powdered polymeric particles a sufficient number of times to produce a time-specific dosage formulation having the desired thickness of swellable polymeric coating layer.

The foregoing and other objects and aspects of the present invention are explained in detail in the detailed description and examples set forth hereinbelow. References referred to herein are incorporated into the present application by reference in their entirety.

10

Detailed Description of the Invention

The methods of the present invention may be employed to achieve the time-specific release of a pharmaceutically active agent and to provide a time-specific controlled-release pharmaceutical formulation for pharmaceutically active agents which are desirously delivered after a predetermined period of time. Suitable pharmaceutically active agents which can be administered by using the methods and formulations of the present invention include pharmaceutically active agents which can be formulated in either solid dosage forms such as tablets, caplets, and capsules as well as pharmaceutically active agents which can be formulated in liquid forms, particularly as liquid-filled capsules. Thus, the methods and 15 formulations of the present invention are suitable for administration of a wide variety of pharmaceutically active agents. More specifically, pharmaceutically active agents which may be employed in the methods of the present invention include, but are not limited to:

steroids such as betamethasone, dexamethasone, methylprednisolone, prednisolone, prednisone, triamcinolone, budesonide, hydrocortisone, and pharmaceutically acceptable hydrocortisone derivatives;

xanthines such as theophylline and doxophylline;

beta-2-agonist bronchodilators such as salbutamol, fenterol, clenbuterol, bambuterol, salmeterol, fenoterol;

antiinflammatory agents, including antiasthmatic anti-inflammatory agents, 30 antiarthritis antiinflammatory agents, and non-steroidal antiinflammatory agents, examples of which include but are not limited to sulfides, mesalamine, budesonide, salazopyrin, diclofenac,

pharmaceutically acceptable diclofenac salts, nimesulide, naproxene, acetominophen, ibuprofen, ketoprofen and piroxicam;

analgesic agents such as salicylates;

calcium channel blockers such as nifedipine, amlodipine, and nicardipine;

5 angiotensin-converting enzyme inhibitors such as captopril, benazepril hydrochloride, fosinopril sodium, trandolapril, ramipril, lisinopril, enalapril, quinapril hydrochloride, and moexipril hydrochloride;

beta-blockers (i.e., beta adrenergic blocking agents) such as sotalol hydrochloride, timolol maleate, esmolol hydrochloride, carteolol, propanolol hydrochloride,

10 betaxolol hydrochloride, penbutolol sulfate, ~~metoprolol tartrate, metoprolol succinate,~~ acebutolol hydrochloride, atenolol, pindolol, and bisoprolol fumarate;

centrally active alpha-2-agonists such as clonidine;

alpha-1-antagonists such as doxazosin and prazosin;

anticholinergic/antispasmodic agents such as dicyclomine hydrochloride,

15 scopolamine hydrobromide, glycopyrrolate, clidinium bromide, flavoxate, and oxybutynin; vasopressin analogues such as vasopressin and desmopressin;

antiarrhythmic agents such as quinidine, lidocaine, tocainide hydrochloride, mexiletine hydrochloride, digoxin, verapamil hydrochloride, propafenone hydrochloride,

flecainide acetate, procainamide hydrochloride, moricizine hydrochloride, and disopyramide phosphate;

20 antiparkinsonian agents, such as dopamine, L-Dopa/Carbidopa, selegiline, dihydroergocryptine, pergolide, lisuride, apomorphine, and bromocryptine;

antiangina agents and antihypertensive agents such as isosorbide mononitrate, isosorbide dinitrate, propranolol, atenolol and verapamil;

25 anticoagulant and antiplatelet agents such as coumadin, warfarin,

~~acetylsalicylic acid, and ticlopidine.~~

sedatives such as benzodiazepines and barbiturates;

anxiolytic agents such as lorazepam, bromazepam, and diazepam;

peptidic and biopolymeric agents such as calcitonin, leuprolide and other

30 LHRH agonists, hirudin, cyclosporin, insulin, somatostatin, protirelin, interferon,

Col 6
Lines 8 - 11

desmopressin, somatotropin, thymopentin, pidotimod, erythropoietin, interleukins, melatonin, granulocyte/macrophage-CSF, and heparin;

antineoplastic agents such as etoposide, etoposide phosphate, cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, doxorubicin, cisplatin,

5 hydroxyurea, leucovorin calcium, tamoxifen, flutamide, asparaginase, altretamine, mitotane, and procarbazine hydrochloride;

laxatives such as senna concentrate, casanthranol, bisacodyl, and sodium picosulphate;

antidiarrheal agents such as difenoxine hydrochloride, loperamide hydrochloride, furazolidone, diphenoxylate hydrochloride, and microorganisms;

vaccines such as bacterial and viral vaccines;

10 antimicrobial agents such as penicillins, cephalosporins, and macrolides'

antifungal agents such as imidazolic and triazolic derivatives; and

nucleic acids such as DNA sequences encoding for biological proteins, and

15 antisense oligonucleotides.

The cores employed in the methods of the present invention may be either solid, tablet-like cores or liquid filled capsule cores. In the case of solid, tablet-like cores, the cores typically include one or more pharmaceutically acceptable excipients in addition to the pharmaceutically active agent. Pharmaceutically acceptable excipients which may be

20 employed are well known to those skilled in the art and include any conventional pharmaceutically acceptable tableting excipients. Examples of suitable excipients include but are not limited to microcrystalline cellulose, dibasic calcium phosphate dihydrate, starch, sodium starch glycolate, crospovidone, croscarmellose sodium, magnesium stearate, lactose, maleic acid, colloidal silicon dioxide, talc, and glyceryl behenate.

25 The core can be prepared by any suitable technique known to those skilled in the art. For example, the pharmaceutically active agent may be admixed with the excipient(s) and advantageously formed into a tablet or caplet using a conventional tableting press.

In the embodiment wherein the core is a capsule containing a liquid form of the pharmaceutically active agent, the pharmaceutically active agent is provided in a liquid

30 form such as a solutions, liposome dispersions, oil-in-water emulsions, microemulsions, precursors of microemulsions and liposomes, dispersions of microparticles, dispersions of

nanoparticles, dispersions of solid lipid nanoparticles, and suspensions. Any conventional technique for providing the active in the form of a solution, liposome dispersions, oil-in-water emulsion, microemulsion, precursors of microemulsion and/or liposomes, dispersions of microparticles, dispersions of nanoparticles, dispersions of solid lipid nanoparticle, or suspension can be employed. Generally, liquid forms of a pharmaceutically active agent can be provided by bringing into association the pharmaceutically active agent and one or more carriers such as by solubilizing, dispersing, or suspending the pharmaceutically active agent in a suitable carrier or emulsifying a liquid containing the pharmaceutically active agent. Of course suitable carriers will be those carriers which do not interfere with the activity of the particular pharmaceutically active agent to be administered, and are pharmaceutically acceptable in the sense that they are not deleterious to the patient to which the formulation will be administered.

Suitable carriers include hydrophilic and lipophilic carriers include, for example, pharmaceutically acceptable alcohols such as ethanol; glycols such as ethoxydiglycol, ethylene glycol, propylene glycol, and polyethylene glycols of varying length (e.g., PEG-4, PEG-6, PEG-8, etc.); alkyl esters of fatty acids such as isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, and polyglyceryl-6 isostearate; mono-, di-, and triglycerides; polyoxyethylene-polyoxypropylene thermosetting copolymers; phospholipids such as phosphatidylcholine; natural and synthetic oils such as hydrogenated coconut oil, palm oil, corn oil, almond oil, white mineral oil, silicon oil, dimethylpolysiloxane; propylene glycol dipelargonate; trilaneth-4-phosphate. Other examples of conventional, suitable hydrophilic and lipophilic carriers which may be employed for the productions of liquid forms of any of the above-listed pharmaceutically active agents can be found in REMINGTON'S

PHARMACEUTICAL SCIENCES, 18th ed. A. Gennaro, Mack Publishing Co., Easton PA (1990).

In some instances it may be desirable to combine two or more hydrophilic carriers, two or more lipophilic carriers, or a combination of an hydrophilic and lipophilic carriers to provide the pharmaceutically active agent in liquid form.

The liquid form of the pharmaceutically active agent may also contain additives such as, for example, conventional dispersants, preservatives, stabilizers, surfactants, antioxidants, buffers, colorants, and the like, as will be understood by those skilled in the art of pharmacy.

Further advantages of the formulation are obtained by including in the liquid form components such as enhancers to improve the intestinal absorption of specific active agents, or enzyme-inhibitors to protect specific active agents from intestinal enzymatic degradation.

5 The pharmaceutically active agents may be formulated into a liquid form using any suitable, conventional techniques known to those skilled in the art of pharmacy. REMINGTON'S PHARMACEUTICAL SCIENCES, 18th ed. A. Gennaro, Mack Publishing Co., Easton PA (1990) as well as many other general pharmacy texts described methods for formulating active agents in solutions, liposome dispersions, oil-in-water emulsions, 10 microemulsions, precursors of microemulsions and/or liposomes, dispersions of microparticles, dispersions of nanoparticles, dispersions of solid lipid nanoparticles, and suspensions; which methods may be employed to provide the pharmaceutically active agent in liquid form according to the present invention.

15 For example, solutions containing pharmaceutically active agents can be produced by substantially completely solubilizing the pharmaceutically active agent in a suitable carrier, optionally with stirring and/or the addition of heat.

Emulsions may be obtained by solubilizing the pharmaceutically active agent in either an aqueous or an oil phase and emulsifying the aqueous and oil phases with the aid of at least one surfactant.

20 The liposome dispersions may be produced according to conventional techniques, through the use of phospholipids after the solubilization of the pharmaceutically active agent. Suitable conventional techniques for the production of liposome dispersions are described in Martindale, 18th Edition, page 1691-1692; Pharmaceutical Manufacturing of Liposomes, F.J. Martin, SPECIALIZED DRUG DELIVERY SYSTEMS, Marcel Dekker Inc., pg. 25 267-316; and Specialized Pharmaceutical Emulsions, M. Rosoff, PHARMACEUTICAL DOSAGE FORMS: DISPERSE SYSTEMS, vol. 1, Marcel Dekker Inc., pg 245-283.

Microemulsions may be obtained as described in Martindale, 18th Ed., pg 1536; and Specialized Pharmaceutical Emulsions, M. Rosoff, PHARMACEUTICAL DOSAGE FORMS: DISPERSE SYSTEMS, vol. 1, Marcel Dekker Inc., pg 245-283.

30 Precursors of microemulsions and liposomes may be obtained in the same way as microemulsions and liposome dispersions, but with less, or no quantity of water.

Microparticles may be obtained as described in Martindale, 18th Edition, page 1663-1664; and Microencapsulation: Scale-Up Considerations and Production Technology, V.A. Crainich, SPECIALIZED DRUG DELIVERY SYSTEMS, Marcel Dekker Inc., pg. 221-255. Dispersions of these microparticles can then be obtained using the dispersion techniques described above.

Nanoparticles may be obtained as described in Martindale, 18th Edition, page 1691; and Large-Scale Production Problems and Manufacturing of Nanoparticles, J. Kreuter, SPECIALIZED DRUG DELIVERY SYSTEMS, Marcel Dekker Inc., pg. 257-266. Dispersions of these nanoparticles can then be obtained using the dispersion techniques described above.

Solid lipid nanoparticles may be obtained as described in Nanoparticelle Lipidiche Solide Quali Sistemi Terapeutici Colloidali, M.R. Gasco, NCF nr. 7, 1996, pg 71-73. Dispersions of these particles can then be obtained using the dispersion techniques described above.

Suspensions may be obtained by suspending the pharmaceutically active agent in a carrier in which it is partially, substantially, or completely insoluble.

The pharmaceutically active agent in liquid form is then encapsulated in a capsule prior to coating the capsule core with the swellable polymeric coating layer by filling the capsule with the liquid form of the pharmaceutically active agent and sealing the capsule to contain the liquid. Any conventional pharmaceutical capsule may be employed. Examples of suitable capsules include gelatin-based capsules (both hard and soft), starch-based capsules, and vegetable-based capsules. Currently soft shell gelatin capsules are preferred for the methods of the present invention. When gelatin or starch capsules are employed, the liquid form of the pharmaceutically active agent preferably includes lipophilic carriers, and in some instances, also hydrophilic carriers in an amount which does not cause the solubilization of the gelatin or starch capsule by the carrier. Typically, the amount of hydrophilic carrier is not more than 30% in those formulations which include by a hydrophilic and a lipophilic carrier. However, this number will differ depending upon the particular capsules employed. Capsule manufacturers typically establish the maximum amount of hydrophilic carrier which can be suitable encapsulated within their particular capsules.

According to the methods of the present invention, the pre-formed core, whether it is a solid, tablet-like core or a liquid filled capsule core, is substantially surrounded

by a swellable polymeric coating layer. The swellable polymeric coating layer delays the release of the pharmaceutically active agent for a predetermined period of time, which period of time is dependent upon the thickness of the swellable polymeric coating layer. In other words, the thicker the swellable polymeric coating, the longer it delays the release of the active ingredient from the core of the formulation. Thus, the appropriate time period for the release of the active ingredient can be determined prior to the preparation of the formulation, and the formulation designed by applying the appropriate thickness of swellable polymeric coating layer to achieve the desired time delay prior to release of the active ingredient.

Typically, the desired time delay will range from about 4 to about 9 hours inclusive, but may be longer or shorter in certain cases.

Because the formulations of the present invention provide the time-delayed release of a pharmaceutically active agent, the formulations provided by the instant invention are useful for the treatment of conditions which are desirously treated through time-delayed pharmaceutical agent delivery mechanisms. For example, the formulations of the present invention are useful for the treatment of morning pathologies, i.e., pathologies, conditions, diseases, or other illnesses, the symptoms of which are generally pronounced, aggravated, or more acute in the morning as the afflicted subject awakens from sleep. The Inventors have filed concurrently herewith, a separate patent application directed toward methods of treating morning pathologies with the time-specific formulations of the present invention. Morning pathologies include arthritis, angina, hypertension, and asthma. These conditions may be advantageously treated by administering the time-specific formulation according to the present invention prior to sleeping such that the delivery of the pharmaceutically active agent is achieved at about the time the afflicted subject awakens, thereby alleviating the symptoms of the morning pathology.

The swellable polymeric coating layer is comprised of two basic components, a binder solution, and powdered polymeric particles. The swellable polymeric coating layer is applied to the core in a two-step fashion, which steps are repeated a sufficient number of times to build the thickness of the swellable polymeric coating layer. In the first step, the core is wet with the binder solution which serves to adhere the powdered polymeric coating particles to the wet core. Suitable binder solutions may include conventional pharmaceutically acceptable binder agents solubilized in a suitable solvent. Specific examples

of binder agents include but are not limited to vinyl polymers, such as polyvinylpyrrolidone, polyvinyl alcohol, and the like; cellulosic polymers, such as hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, and the like; acrylic polymers and copolymers such as methacrylic acid copolymers, ethyl acrylate-methylmethacrylate copolymers, and the like; natural or synthetic gums, such as guar gum, arabic gum, xanthan gum, and the like; proteins or carbohydrates, such as gelatin, pectin, and the like; and mixtures thereof.

Currently, polyvinylpyrrolidone is the preferred binder agent.

Suitable solvents for solubilizing the binder agents include solvents which are capable of substantially completely solubilizing the specific binder agent(s) selected and which are pharmaceutically and biologically acceptable for ingestion. Suitable solvents will be readily determinable by those skilled in the art. Water is currently the preferred solvent for solubilizing the binder agent, as it is pharmacologically and biologically well suited for ingestion. However, other examples of suitable solvents will be appreciated by those skilled in the art and are contemplated by the methods of the present invention.

The binder solution should be of sufficient viscosity to enable the wetting of the cores by any suitable wetting technique known to those skilled in the art. For example, the cores may be wetted with the binder solution by rotating the cores in a bath containing the binder solution. The cores may be suitably wetted by manual application of the binder solution by ladling the binder solution over the cores as the cores are rotating in a conventional coating pan. Alternatively, the cores may be wetted by spraying the binder solution on the cores. In one embodiment, the wetting step is advantageously carried out using conventional automated pan coating equipment wherein the cores are sprayed with the binder solution while rotating in the pan.

To provide the coating layer, the wetted cores are coated with dry, powdered polymeric coating particles which adhere to the binder-wetted core due to the presence of the binder on the surface of the core. The polymeric coating particles typically comprise a hydrophilic gelling polymer or "swellable" polymer which swells on contact with gastrointestinal juices to form a continuous film surrounding the core. The coating layer must sufficiently protect the integrity of the core for the desired period of time, without regard to the pH of the medium to which it is subjected. Once the desired, pre-delivery time period has elapsed, the coating layer should be almost completely dissolved or eroded so that the core

should be capable of relatively quick disintegration. Thus, it is desirable that the core be capable of the fast, time-specific release of the pharmaceutically active agent. Significantly, the methods of the present invention do not require polymeric solutions for the formation of the swellable polymeric coating layer and as such provide distinct advantages in terms of ease of manufacture and decreased manufacturing time. Because the methods of the present invention do not utilize polymeric solutions for the formation of the swellable polymeric coating layer, but instead utilize dry powdered polymeric particles, polymers which exhibit high viscosity in solution may be used in the methods of the present invention although they may not be functional in conventional film coating methods.

The polymeric coating particles may be comprised of any suitable hydrophilic gelling polymer known to those skilled in the art. For example, suitable hydrophilic gelling polymers include but are not limited to cellulosic polymers, such as methylcellulose, carboxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, and the like; vinyl polymers, such as polyvinylpyrrolidone, polyvinyl alcohol, and the like; acrylic polymers and copolymers, such as acrylic acid polymer, methacrylic acid copolymers, ethyl acrylate-methyl methacrylate copolymers, and the like; and mixtures thereof. Currently, the preferred polymeric particles comprise hydroxypropylmethylcellulose.

Hydroxypropylmethylcellulose is a polymer which is available in many forms, including forms of different molecular weight, extremely different viscosity and different substitution grade. The inventors have also discovered that it is advantageous in certain applications to utilize mixtures or blends of two or more different forms of hydroxypropylmethylcellulose as the polymeric coating particles. In one preferred embodiment, the polymeric coating particles of the coating layer comprise a mixture of polymeric coating particles having differing molecular weights and solubility characteristics. For example, the coating layer may be comprised of polymeric coating particles comprising a mixture of *a*) hydroxypropylmethylcellulose having *I*) a typical weight percent substitution corresponding to 29% methoxyl and 8% hydroxypropoxyl groups, and *ii*) a nominal viscosity of a 2% watery solution at 20°C ranging from 5 to 100 mPa.s; and *b*) hydroxypropylmethylcellulose having *I*) a typical weight percent substitution corresponding to 22.1% methoxyl and 8.1% hydroxypropoxyl groups, and *ii*) a nominal viscosity of a 2%

watery solution at 20°C ranging from 4,000 to 100,000 mPa.s. An example of the first type of hydroxypropylmethylcellulose is METHOCEL E5®, and an example of the second type is METHOCEL K15M®, both of which are commercially available from Colorcon.

The polymer(s) of the swellable polymeric coating layer partially hydrates on the outer surface thereof after ingestion to form a gel-like layer that acts as a skin, controlling the rate of erosion of the coating layer. As a consequence, the release or delivery of the pharmaceutically active agent contained within the core is inhibited for the predetermined period of time.

Grades of hydroxypropylmethylcellulose having different degrees of substitution also possess different rates of hydration. The inventors have discovered that by utilizing mixtures or blends of two or more polymers with different rates of hydration, it is possible to obtain a layer with improved characteristics in terms of the rate-controlled hydration of the same.

Because the formulations and methods of the present invention may include either a single hydroxypropylmethylcellulose or a blend of two or more different forms of hydroxypropylmethylcellulose as the powdered polymeric coating particles, for simplicity, the term "hydroxypropylmethylcellulose" as used herein, including the claims, refers to either a single hydroxypropylmethylcellulose or a blend of two or more forms of the polymer.

Alternatively, the swellable polymeric coating layer may be comprising of other substances which are capable of becoming freely permeable with an exactly defined kinetic following hydration in aqueous fluids. Such substances include polysaccharides, such as gelatin, saccharose, ~~sorbitol~~, mannanes, and jaluronic acid; polyaminoacids; polyalcohols; polyglycols; and the like.

In addition to the foregoing, the swellable polymeric coating layer may also include additional excipients such as lubricants, flow promoting agents, plasticizers, antisticking agents, natural and synthetic flavorings and natural and synthetic colorants.

Specific examples of additional excipients include polyethylene glycol, polyvinylpyrrolidone, talc, magnesium stearate, glycetyl behenate, stearic acid, and titanium dioxide.

After the powdered polymeric coating particles are applied to the wetted core, the steps of first, wetting the core with binder and second, coating with powdered polymeric coating particles are repeated sequentially one or more additional times in order to build the

Excipients for
coating

thickness of the swellable polymeric coating layer around the core. In other words, the alternating steps of wetting the core and coating with powdered polymeric coating particles are repeated in alternate fashion so that prior to each application of the powdered coating particles, the core is first wetted with binder solution. In this manner of repeated alternate applications of binder solution and powdered polymeric coating particles, the thickness of the swellable polymeric coating layer is increased to the desired measure. The number of repeated wetting and coating cycles is dependent upon the desired predetermined time for delivery of the active ingredient. The thicker the swellable polymeric coating layer around the core, the longer the latency, or lag time prior to delivery of the active ingredient. Typically, a sufficient number of wetting and coating cycles are performed so as to produce a core:coating layer weight ratio of between about 20:1 and about 1:5 inclusive, or a thickness in excess of about 10 μm , and up to about 3 mm. Preferably, a sufficient number of coating cycles are completed so as to produce a core:coating layer weight ratio of between about 5:1 and about 1:3 inclusive, or a thickness of between about 50 μm and about 1.5 mm.

In an alternate embodiment of the present invention, the swellable polymeric coating layer may be applied to the core using conventional film (or spray) coating techniques or double press coating techniques which are known to those skilled in the art of pharmacy. In the embodiment wherein the swellable polymeric coating layer is applied to the core using film coating techniques, the hydrophilic gelling polymer is solubilized in an aqueous solution. Typically, the polymer used for film coating exhibits a viscosity ranging from about 3 to 100 mPa.s. at 25°C in a 2% aqueous solution.

Although some organic solvents may be employed in the film coating application of the swellable polymeric coating layer, the inclusion of organic solvents in the film coating solution utilized in the methods of the present invention is not required.

The solution of hydrophilic gelling polymer can be applied to the core by any means of film coating including but not limited to fluid bed, or pan coating. Preferably, the solution of polymer is sprayed on the core to form the swellable polymeric coating layer.

The polymer is applied on the core in order to build the desired thickness of the swellable polymeric coating layer. For example, in the embodiment wherein film coating is employed, the core is sprayed with the solution of polymer until the desired thickness of

swellable polymeric coating layer is achieved. The desired thicknesses are the same as described above for the alternate method or preparing these formulations.

The methods of the present invention provide a time-specific dosage formulation which is suitable for oral administration and delivery in the gastro-intestinal tract. The formulation includes (a) a core comprising the pharmaceutically active agent, and (b) a swellable polymeric coating layer substantially surrounding the core. In one embodiment the core comprises a solid, tablet-like core. In another embodiment, the core comprises a liquid-filled capsule core. As described hereinabove, the swellable polymeric coating layer is applied or provided by alternately wetting the core with a binder solution and coating the core with powdered polymeric particles a sufficient number of times to produce a time-specific dosage formulation having the desired thickness of swellable polymeric coating layer. The number of alternate wetting and coating processes depends upon the desired thickness of the coating layer, which in turn determines the lag time within the body after administration, prior to delivery of the pharmaceutically active agent.

Accordingly the methods of the present invention also include methods of achieving the time-specific delivery of a pharmaceutically active agent to a patient in need of the therapeutic effects of the pharmaceutically active agent. The method includes administering to the patient the time-specific release dosage form described hereinabove.

Suitable patient populations for which the methods of the present invention are directed include mammals in general, and in particular, humans.

The following examples are provided to illustrate the present invention, and should not be construed as limiting thereof. In these examples, " μg " means micrograms, "mg" means milligrams, "g" means grams, "mm" means millimeters, " μm " means micrometers, "kp" means 9.807 Newton, "mPa.s" means milliPascal per second, "min." means minute(s), and " $^{\circ}\text{C}$ " means degrees Centigrade. All percentages are in percent by weight of the tablet unless otherwise indicated. Disintegration tests are carried out according to the standard procedures set forth in the United States Pharmacopoeia for testing the disintegration of tablets.

EXAMPLE 1

Diclofenac sodium (25 mg), 140 mg of dibasic calcium phosphate dihydrate, 24 mg of microcrystalline cellulose, and 10 mg of sodium starch glycolate, are mixed thoroughly. Magnesium stearate (1 mg) is added and thoroughly mixed for another 5 min.

5 The granular mixture is formed into tablet cores of 6.8 mm diameter, weighing 200 mg each, using a rotary tablet press. The cores show a disintegration time lower than 5 min. in water, a Schleuninger hardness higher than 10 kp and a friability lower than 0.1%.

The cores are heated to 40°C and the coating layer is applied onto the cores in a two-step procedure, using an automatic coating pan. In the first step, the cores are wetted with a binder solution including 15% polyvinylpyrrolidone, and 85% purified water. In the second step, the wetted cores are treated with a dry mixture including 22.5% METHOCEL E5®, 67.5% METHOCEL K15M®, 9% talc and 1% colloidal silicon dioxide. Steps 1 and 2 are repeated until a weight gain corresponding to 30% of total tablet weight is achieved. The time necessary to apply a weight gain of 30% has been less than 3 hours.

15 The coated tablets show a dissolution time lag in excess of 302±56 min, indicating that there is no release of diclofenac from the core in the first 5 hours.

EXAMPLE 2**Comparative Example -Spray Coating**

20 Cores (20,000) containing 25 mg diclofenac sodium are prepared according to

Example 1.

The cores are heated to 40°C and the coating layer is applied by continuously spraying the cores with a solution including 7.5% METHOCEL E50®, 0.5% PEG 6000®, and 92% purified water, until a weight gain corresponding to 60% of the tablet weight is achieved. The coating time corresponds to 5 days.

25 The coated tablets show a dissolution time lag in excess of 300 min., followed by a quick disintegration of the tablet.

EXAMPLE 3

30 Verapamil HCl (40 mg), 129 mg of dibasic calcium phosphate dihydrate, 20 mg of microcrystalline cellulose, and 10 mg of sodium starch glycolate, are mixed thoroughly.

Magnesium stearate (1 mg) is added and thoroughly mixed for another 5 min. The granular mixture is formed into tablet cores of 6.8 mm diameter, weighing 200 mg each using a rotary tablet press. The cores show a disintegration time lower than 5 min. in water, a Schleuninger hardness higher than 10 kp and a friability lower than 0.1%.

5 The cores are heated to 40°C and the coating layer is applied onto the cores in a two-step procedure, using an automatic coating pan. In the first step, the cores are wetted with a binder solution including 5% METHOCEL E5®, 10% polyvinylpyrrolidone, and 85% purified water. In the second step, the wetted cores are treated with a dry mixture including 90% METHOCEL K15M®, 9% talc and 1% colloidal silicon dioxide. Steps 1 and 2 are
10 repeated until a weight gain corresponding to 50% of total tablet weight is achieved.

The coated tablets showed a dissolution time lag in excess of 300 min., followed by a quick disintegration of the tablet.

EXAMPLE 4

15 Isosorbide-5-mononitrate (20 mg), 135 mg of Lactose S.D. 34 mg of microcrystalline cellulose, and 10 mg of sodium starch glycolate, are mixed thoroughly. Magnesium stearate (1 mg) is added and thoroughly mixed for another 5 min. The granular mixture is formed into tablet cores of 6.8 mm diameter, weighing 200 mg each using a rotary tablet press. The cores show a disintegration time lower than 5 min. in water, a Schleuninger
20 hardness higher than 10 kp and a friability lower than 0.1%.

The cores are heated to 40°C and the coating layer is applied onto the cores in a two-step procedure, using an automatic coating pan. In the first step, the cores are wetted with a binder solution including 7% METHOCEL E50®, 3% PEG 400®, and 90% purified water. In the second step, the wetted cores are treated with a dry mixture including 90% METHOCEL K15M®, 9% talc and 1% colloidal silicon dioxide. Steps 1 and
25 2 are repeated until a weight gain corresponding to 70% of total-tablet weight is achieved. Samples corresponding to weight gains of 25, 50, and 70% were collected.

The coated tablets showed a disintegration time lag linearly proportional to the amount of coating layer applied, until a time lag corresponding to 8 hours for the last sample.

EXAMPLE 5

Tablet cores containing 1 mg of lorazepam as the active ingredient are heated to 40°C and coated in a two-step procedure, using an automatic coating pan. In the first step, the cores are wetted with a binder solution including 15% polyvinylpyrrolidone and 85% purified water. In the second step, the wetted cores are treated with a dry mixture including 45% METHOCEL E5®, 45% NATROSOL HHR®, 9% talc and 1% colloidal silicon dioxide. Steps 1 and 2 are repeated until a weight gain corresponding to 35% of total tablet weight is achieved. The coating layer is determined to be approximately 0.7-0.8 mm in thickness. The coating time corresponds to 6 hours. The coated tablets showed a disintegration time lag in excess of 300 min.

EXAMPLE 6**Comparative Example -Fluid Bed Coating**

Tablets containing 1 mg of lorazepam are coated with a coating layer using a fluid bed apparatus. The cores are heated to 40°C and the coating layer is applied by continuously spraying a solution including 7.5% METHOCEL E50®, 0.5% PEG 6000®, 1% colloidal silicon dioxide, and 91% purified water, until a layer corresponding to 50% of weight gain is applied. The coating time corresponds to 5 days. The coated tablets showed a disintegration time lag in excess of 300 min.

20

EXAMPLE 7

Bromocryptine mesylate (2.87 mg), 30 mg of microcrystalline cellulose, and 2 mg of maleic acid are mixed thoroughly. Lactose S.D. (153.78 mg), 10 mg of sodium starch glycolate, 0.35 mg colloidal silicon dioxide, and magnesium stearate (1 mg) are added and thoroughly mixed for another 10 min. The granular mixture is formed into tablet cores of 6.8 mm diameter, weighing 200 mg using a rotary tablet press. The cores show a disintegration time lower than 5 min. in water, a Schleuninger hardness higher than 10 kp and a friability lower than 0.1%.

30

The cores are heated to 40°C and the coating layer is applied onto the cores in a two-step procedure, using an automatic coating pan. In the first step, the cores are wetted with a binder solution including 7% METHOCEL E50®, 3% PEG 400®,

and 90% purified water. In the second step, the wetted cores are treated with a dry mixture including 90% METHOCEL K15M®, 9% talc and 1% colloidal silicon dioxide. Steps 1 and 2 are repeated until a weight gain corresponding to 50% of total tablet weight is achieved. The coated tablets showed a disintegration time lag in excess of 5 hours.

5

EXAMPLE 8

Sugar pellets (15 kg) having a diameter of 0.4-0.6 mm were increased with diclofenac sodium, in a two-step procedure using an automatic rotary pan. First, the pellets are wetted with a 30% aqueous suspension of acrylic and methacrylic copolymer soluble in 10 gastric medium. Second, the wetted pellets are treated with a dry mixture including 90.1% diclofenac sodium, 9% talc, and 0.9% colloidal silicon dioxide. These steps are repeated until a diclofenac sodium potency of 50% is achieved.

The core pellets are coated with the coating layer in a two-step procedure, using an automatic coating pan. In the first step, the core pellets are wetted with a binder 15 solution including 15% polyvinylpyrrolidone and 85% purified water. In the second step, the wetted core pellets are treated with a dry mixture including 80% METHOCEL K15M®, and 20% talc. Steps 1 and 2 are repeated until a weight gain corresponding to 75% of total pellet weight is achieved. An amount of coated pellets corresponding to 100 mg of diclofenac sodium is encapsulated in a hard shell gelatin capsule to provide a single dosage form. The

20 capsule showed a disintegration time lag in excess of 6 hours.

EXAMPLE 9

~~Cyclosporin A (100 mg), 140 mg dibasic calcium phosphate dihydrate, 25 mg of microcrystalline cellulose, 11 mg of sodium starch glycolate, and 0.5 mg of colloidal silicon dioxide are mixed thoroughly. Glyceryl behenate (3.5 mg) is added and thoroughly mixed for another 5 min. The granular mixture is formed into tablet cores of 8.7 mm diameter, weighing 280 mg using a rotary tablet press. The cores show a disintegration time lower than 5 min. in water, a Schleuninger hardness higher than 10 kp and a friability lower than 0.1%.~~

The cores are heated to 40°C and the coating layer is applied onto the cores in 30 a two-step procedure, using an automatic coating pan. In the first step, the cores are wetted with a binder solution including 15% polyvinylpyrrolidone, and 85% purified water. In the

second step, the wetted cores are treated with a dry mixture including 45% METHOCEL E5®, 45% METHOCEL K15M®, 9% talc and 1% colloidal silicon dioxide. Steps 1 and 2 are repeated until a weight gain corresponding to 50% of total tablet weight is achieved. The coated tablets showed a disintegration time lag in excess of 6 hours.

5

EXAMPLE 10

Insulin (100 I.U.), aprotinin (100,000 I.U.), poloxamer F127 (45 mg), purified water (15 mg), PEG-8 caprylic/capric glycerides (90 mg), and isopropyl myristate (q.s. to 300 mg) are mixed until solubilization.

10

The obtained solution is dosed into 5 oval-shaped soft gelatin capsules formed from gelatin (106.0 mg), glycerin (41.7 mg), red iron oxide (1.7 mg), sodium ethyl paraben (0.4 mg), and sodium propylparaben (0.2 mg).

The capsules show a disintegration time lower than 5 min. in water.

15

The capsules are heated to 35°C and the coating layer is applied onto the cores in a two-step procedure, using an automatic coating pan. In the first step, the cores are wetted with a binder solution including 5% METHOCEL E5®, 0.5% gelatin, and 94.5% purified water. In the second step, the wetted cores are treated with a dry mixture including 90% METHOCEL K15M®, 9% talc and 1% colloidal silicon dioxide. Steps 1 and 2 are repeated until a weight gain corresponding to 30% of total capsule weight is achieved.

20

The coated capsules showed a dissolution time in excess of 240 min., followed by a quick disintegration of the capsule.

EXAMPLE 11

Cyclosporin A (100 mg), ethyl alcohol (80 mg), poloxamer F127 (75 mg), purified water (25 mg), cocamide DEA (85 mg), and isopropyl myristate (135 mg) are mixed until solubilization.

The obtained microemulsion is dosed into 8 oblong-shaped, soft gelatin capsules, formed from gelatine (216.9 mg), glycerin (3.7 mg), sorbitol 70% (75.9 mg), and titanium dioxide (3.5 mg).

30

The capsules are heated to 30-35°C and coated in a two-step procedure, using an automatic coating pan. In the first step, the capsules are wetted with a binder solution

including 15% polyvinylpyrrolidone, 1% gelatin, and 84% purified water. In the second step, the wetted cores are treated with a dry mixture including 45% METHOCEL E5®, 45% METHOCEL K15M®, 9% talc, and 1% colloidal silicon dioxide. Steps 1 and 2 are repeated until a weight gain corresponding to 50% of total capsule weight is achieved. The coated capsules showed a disintegration time lag in excess of 5 hours.

EXAMPLE 12

The capsules of Example 11 are heated to 30-35°C and coated by continuously spraying a solution including 7.5% METHOCEL E50®, 0.5% PEG 6000, 1% 10 colloidal silicon dioxide, and 91% purified water, until a weight gain corresponding to 30% of total capsule weight is achieved. The coated capsules showed a disintegration time lag in excess of 240 min.

EXAMPLE 13

15 Etoposide (50 mg), ethoxydiglycol (86.5 mg), apricot kernel oil PEG-6 esters (27.9 mg), caprylic/capric triglyceride (55.9 mg), polyglyceryl-6 isostearate (72.6 mg), PEG-8 caprylic/capric glycerides (251.3 mg), and purified water (55.8 mg) are mixed until solubilized in the form of a microemulsion.

20 The obtained microemulsion is dosed into 10 oval-shaped, soft gelatin capsules, formed from gelatin (185 mg), glycerol (90 mg), sodium ethyl paraben (0.8 mg), sodium propylparaben (0.4 mg), titanium dioxide (2.7 mg), yellow iron oxide (0.2 mg), PEG 20000 (7 mg), and PEG 1550 (3 mg).

25 The capsules are heated to 30-35°C and the coating layer is applied onto the capsules in a two-step procedure, using an automatic coating pan. In the first step, the capsules are wetted with a binder solution including 7% METHOCEL E50®, 3% PEG 400, and 90% purified water. In the second step, the wetted capsules are treated with a dry mixture including 22.5 % METHOCEL E5®, 67.5% METHOCEL K15M®, 9% talc, and 1% colloidal silicon dioxide. Steps 1 and 2 are repeated until a weight gain corresponding to 30% of total capsule weight is achieved. The coated capsules show a dissolution time lag in excess of 240 min.

EXAMPLE 14

5 *Staphylococcus aureus* (2 mg, corresponding to 10^9 bacteria), *Escherichia coli* (2 mg, corresponding to 10^9 bacteria), *Aerobacter aerogenes* (2 mg, corresponding to 10^9 bacteria), *Proteus vulgaris* (2 mg, corresponding to 10^9 bacteria), and PEG 400 are mixed thoroughly.

The obtained dispersion is dosed into 3 oval-shaped, soft gelatin capsules, formed from gelatin (67 mg), glycerin (33 mg), sodium ethyl paraben (0.3 mg), sodium propylparaben (0.2 mg), and E127 (0.02 mg).

10 The capsules are heated to 30°C and the coating layer is applied onto the capsules in a two-step procedure, using an automatic coating pan. In the first step, the capsules are wetted with a binder solution including 15% polyvinylpyrrolidone, and 85% purified water. In the second step, the wetted capsules are treated with a dry mixture including 45% METHOCEL E5®, 45% NATROSOL HHR®, 9% talc, and 1% colloidal silicon dioxide. Steps 1 and 2 are repeated until a weight gain corresponding to 30% of total
15 capsule weight is achieved. The coated capsules showed a disintegration time lag in excess of 240 min.

EXAMPLE 15

20 Salmon calcitonin (500 I.U.), sodium methylparaben (1.5 mg), disodium edetate (10.3 mg), sodium cholate (10.3 mg), and purified water (40.6 mg) are solubilized, and the temperature increase to 60°C.

Egg phosphatidylcholine (38.6 mg), cholesterol (7.8 mg), ethyl alcohol (61.7 mg), and tocopherol acetate (0.2 mg) are solubilized, and the temperature increased to 60°C.

25 The obtained liposome dispersion is dosed into 3 oval soft gelatin capsules, formed by gelatin (67 mg), glycerin (33 mg), sodium ethyl paraben (0.3 mg), sodium propylparaben (0.2 mg), and E127 (0.02 mg).

30 The capsules are heated to 25-30°C and the coating layer is applied onto the cores in a two-step procedure, using an automatic coating pan. In the first step, the capsules are wetted with a binder solution including 7% METHOCEL E50®, 3% PEG 400, 70% ethyl alcohol, and 20% purified water. In the second step, the wetted cores are treated with a dry mixture including 90% METHOCEL K15M®, 9% talc, and 1% colloidal silicon dioxide.

Steps 1 and 2 are repeated until a weight gain corresponding to 30% of total capsule weight is achieved. The coated capsules showed a disintegration time lag in excess of 240 min.

The foregoing is illustrative of the present invention and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the 5 claims to be included therein.

That Which Is Claimed Is:

1 1. A method for time-specific delivery of a pharmaceutically active agent
2 to a patient in need of the therapeutic effects of said pharmaceutically active agent, said
3 method comprising administering to said patient, a pharmaceutical formulation comprising (a)
4 a core comprising said pharmaceutically active agent, and (b) a swellable polymeric coating
5 layer substantially surrounding said core, that delays the release of said pharmaceutically
6 active agent from said core for a predetermined period of time dependent upon the thickness
7 of said swellable polymeric coating layer; and wherein said swellable polymeric coating layer
8 is provided by alternately (i) wetting said core with a binder solution, and (ii) coating said
9 core with powdered polymeric particles a sufficient number of times to produce a time-
10 specific dosage formulation having the desired thickness of swellable polymeric coating layer.

1 2. The method according to Claim 1, wherein said pharmaceutical
2 formulation is administered orally.

1 3. The method according to Claim 1, wherein said pharmaceutically
2 active agent is selected from the group consisting of steroids, xanthines, beta-2-agonist
3 bronchodilators, anti-inflammatory agents, analgesic agents, calcium antagonists, angiotensin-
4 converting enzyme inhibitors, beta-blockers, centrally active alpha-agonists, alpha-1-
5 antagonists, anticholinergic/antispasmodic agents, vasopressin analogues, antiarrhythmic
6 agents, antiparkinsonian agents, antiangina/antihypertensive agents, anticoagulant agents,
7 antiplatelet agents, sedatives, anxiolytic agents, peptidic agents, biopolymeric agents,
8 antineoplastic agents, laxatives, antidiarrheal agents, antimicrobial agents, antifungal agents,
9 vaccines, and nucleic acids.

1 4. The method according to Claim 1, wherein said swellable polymeric
2 coating layer comprises powdered polymeric particles selected from the group consisting of
3 hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose,
4 polyvinylpyrrolidone, polyvinyl alcohol, acrylic acid polymer, methacrylic acid copolymers,
5 ethyl acrylate-methyl methacrylate copolymers, and mixtures thereof.

1 5. The method according to Claim 1, wherein said binder solution is
2 selected from the group consisting of polyvinylpyrrolidone, hydroxypropylmethylcellulose,
3 polyvinyl alcohol, hydroxyethylcellulose, methacrylic acid copolymers, ethylacrylate-
4 methylmethacrylate copolymers, guar gum, arabic gum, xanthan gum, gelatin, pectin, and
5 mixtures thereof.

1 6. The method according to Claim 1, wherein said swellable polymeric
2 coating layer comprises polymeric hydroxypropylmethylcellulose particles.

1 7. The method according to Claim 1, wherein said binder solution is
2 polyvinylpyrrolidone.

1 8. The method according to Claim 1, wherein said swellable polymeric
2 coating layer is not less than 50 μm thick.

1 9. The method according to Claim 1, wherein said swellable polymeric
2 coating layer is sufficiently thick to achieve a core:coating layer ratio of between about 20:1
3 to about 1:5.

1 10. The method according to Claim 1, wherein said swellable polymeric
2 coating layer is sufficiently thick to achieve a core:coating layer ratio of between about 5:1 to
3 about 1:3.

1 11. A method for time-specific delivery of a pharmaceutically active agent
2 to a patient in need of the therapeutic effects of said pharmaceutically active agent, said
3 method comprising administering to said patient, a pharmaceutical formulation comprising (a)
4 a core comprising said pharmaceutically active agent, and (b) a swellable polymeric coating
5 layer substantially surrounding said core, that delays the release of said pharmaceutically
6 active agent from said core for a predetermined period of time dependent upon the thickness

7 of said swellable polymeric coating layer; and wherein said swellable polymeric coating layer
8 is formed from powdered polymeric particles.

1 12. A method for producing a time-specific dosage formulation for the
2 time-specific delivery of a pharmaceutically active agent, said method comprising coating a
3 core comprising said pharmaceutically active agent with a swellable polymeric coating layer
4 that delays the release of said pharmaceutically active agent from said core for a
5 predetermined period of time dependent upon the thickness of said swellable polymeric
6 coating layer; and wherein said step of coating said core with said swellable polymeric coating
7 layer comprises alternately (i) wetting said core with a binder solution, and (ii) coating said
8 core with powdered polymeric particles a sufficient number of times to produce a time-
9 specific dosage formulation having the desired thickness of swellable polymeric coating layer.

1 13. The method according to Claim 12, wherein said pharmaceutically
2 active agent is selected from the group consisting of steroids, xanthines, beta-2-agonist
3 bronchodilators, anti-inflammatory agents, analgesic agents, calcium antagonists, angiotensin-
4 converting enzyme inhibitors, beta-blockers, centrally active alpha-agonists, alpha-1-
5 antagonists, anticholinergic/antispasmodic agents, vasopressin analogues, antiarrhythmic
6 agents, antiparkinsonian agents, antiangina/antihypertensive agents, anticoagulant agents,
7 antiplatelet agents, sedatives, anxiolytic agents, peptidic agents, biopolymeric agents,
8 antineoplastic agents, laxatives, antidiarrheal agents, antimicrobial agents, antifungal agents,
9 vaccines, and nucleic acids.

1 14. The method according to Claim 12, wherein said swellable polymeric
2 coating layer comprises powdered polymeric particles selected from the group consisting of
3 hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose,
4 polyvinylpyrrolidone, polyvinyl alcohol, acrylic acid polymer, methacrylic acid copolymers,
5 ethyl acrylate-methyl methacrylate copolymers, and mixtures thereof.

1 15. The method according to Claim 12, wherein said binder solution is
2 selected from the group consisting of polyvinylpyrrolidone, hydroxypropylmethylcellulose,

3 polyvinyl alcohol, hydroxyethylcellulose, methacrylic acid copolymers, ethylacrylate-
4 methylmethacrylate copolymers, guar gum, arabic gum, xanthan gum, gelatin, pectin, and
5 mixtures thereof.

1 16. The method according to Claim 12, wherein said step of coating said
2 core with said swellable polymeric coating layer comprises coating said core with a swellable
3 polymeric coating layer not less than 50 μm thick.

4

5 17. The method according to Claim 12, wherein said step of coating said
6 core with said swellable polymeric coating layer comprises coating said core with a swellable
7 polymeric coating layer to achieve a core:coating layer ratio of between about 20:1 to about
8 1:5.

1 18. A method for time-specific delivery of a pharmaceutically active agent
2 to a patient in need of the therapeutic effects of said pharmaceutically active agent, said
3 method comprising administering to said patient, a pharmaceutical formulation comprising:
4 (a) a core which comprises a capsule containing a liquid form of said pharmaceutically active
5 agent, and (b) a swellable polymeric coating layer substantially surrounding said core, that
6 delays the release of said pharmaceutically active agent from said core for a predetermined
7 period of time dependent upon the thickness of said swellable polymeric coating layer; and
8 wherein said swellable polymeric coating layer is provided by alternately (I) wetting said core
9 with a binder solution, and (ii) coating said core with powdered polymeric particles a
10 sufficient number of times to produce a time-specific dosage formulation having the desired
11 thickness of swellable polymeric coating layer.

1 19. The method according to Claim 18, wherein said pharmaceutical
2 formulation is administered orally.

1 20. The method according to Claim 18, wherein said liquid form of said
2 pharmaceutically active agent is selected from the group consisting of solutions, liposome
3 dispersions, oil-in-water emulsions, microemulsions, precursors of microemulsions and

4 liposomes, dispersions of microparticles, dispersions of nanoparticles, dispersions of solid
5 lipid particles, and suspensions.

1 21. The method according to Claim 18, wherein said pharmaceutically
2 active agent is selected from the group consisting of steroids, xanthines, beta-2-agonist
3 bronchodilators, anti-inflammatory agents, analgesic agents, calcium antagonists, angiotensin-
4 converting enzyme inhibitors, beta-blockers, centrally active alpha-agonists, alpha-1-
5 antagonists, anticholinergic/antispasmodic agents, vasopressin analogues, antiarrhythmic
6 agents, antiparkinsonian agents, antiangina/antihypertensive agents, anticoagulant agents,
7 antiplatelet agents, sedatives, anxiolytic agents, peptidic agents, biopolymeric agents,
8 antineoplastic agents, laxatives, antidiarrheal agents, antimicrobial agents, antifungal agents,
9 vaccines, and nucleic acids.

1 22. The method according to Claim 18, wherein said swellable polymeric
2 coating layer comprises powdered polymeric particles selected from the group consisting of
3 hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose,
4 polyvinylpyrrolidone, polyvinyl alcohol, acrylic acid polymer, methacrylic acid copolymers,
5 ethyl acrylate-methyl methacrylate copolymers, and mixtures thereof.

1 23. The method according to Claim 18, wherein said binder solution is
2 selected from the group consisting of polyvinylpyrrolidone, hydroxypropylmethylcellulose,
3 polyvinyl alcohol, hydroxyethylcellulose, methacrylic acid copolymers, ethylacrylate-
4 methylmethacrylate copolymers, guar gum, arabic gum, xanthan gum, gelatin, pectin, and
5 mixtures thereof.

1 24. The method according to Claim 18, wherein said swellable polymeric
2 coating layer comprises polymeric hydroxypropylmethylcellulose particles.

1 25. The method according to Claim 18, wherein said binder solution is
2 polyvinylpyrrolidone.

3 26. The method according to Claim 18, wherein said swellable polymeric
4 coating layer is not less than 50 μm thick.

1 27. The method according to Claim 18, wherein said swellable polymeric
2 coating layer is sufficiently thick to achieve a core:coating layer ratio of between about 20:1
3 to about 1:5.

1 28. The method according to Claim 18, wherein said swellable polymeric
2 coating layer is sufficiently thick to achieve a core:coating layer ratio of between about 5:1 to
3 about 1:3.

4 29. A method for time-specific delivery of a pharmaceutically active agent,
1 to a patient in need of the therapeutic effects of said pharmaceutically active agent, said
2 method comprising administering to said patient, a pharmaceutical formulation comprising:
3 (a) a core which comprises a capsule containing a liquid form of said pharmaceutically active
4 agent, and (b) a swellable polymeric coating layer substantially surrounding said core, that
5 delays the release of said pharmaceutically active agent from said core for a predetermined
6 period of time dependent upon the thickness of said swellable polymeric coating layer; and
7 wherein said swellable polymeric coating layer is formed from powdered polymeric particles.

1 30. A method for producing a time-specific dosage formulation for time-
2 specific delivery of a pharmaceutically active agent, said method comprising coating a core
3 which comprises a capsule containing a liquid form of said pharmaceutically active agent, with
4 a swellable polymeric coating layer that delays the release of said pharmaceutically active
5 agent from said core for a predetermined period of time dependent upon the thickness of said
6 swellable polymeric coating layer, wherein said step of coating said core with said swellable
7 polymeric coating layer comprises alternately (i) wetting said core with a binder solution, and
8 (ii) coating said core with powdered polymeric particles a sufficient number of times to
9 produce a time-specific dosage formulation having the desired thickness of swellable
10 polymeric coating layer.

1 31. The method according to Claim 30 further comprising the steps of (1)
2 providing a liquid form of said pharmaceutically active agent selected from the group
3 consisting of solutions, liposome dispersions, oil-in-water emulsions, microemulsions,
4 precursors of microemulsions and liposomes, dispersions of microparticles, dispersions of
5 nanoparticles, dispersions of solid lipid particles, and suspensions, and (2) encapsulating said
6 liquid form of said pharmaceutically active agent in a capsule, prior to said step of coating
7 said core.

1 32. The method according to Claim 30, wherein said pharmaceutically
2 active agent is selected from the group consisting of steroids, xanthines, beta-2-agonist
3 bronchodilators, anti-inflammatory agents, analgesic agents, calcium antagonists, angiotensin-
4 converting enzyme inhibitors, beta-blockers, centrally active alpha-agonists, alpha-1-
5 antagonists, anticholinergic/antispasmodic agents, vasopressin analogues, antiarrhythmic
6 agents, antiparkinsonian agents, antiangina/antihypertensive agents, anticoagulant agents,
7 antiplatelet agents, sedatives, anxiolytic agents, peptidic agents, biopolymeric agents,
8 antineoplastic agents, laxatives, antidiarrheal agents, antimicrobial agents, antifungal agents,
9 vaccines, and nucleic acids.

1 33. The method according to Claim 30, wherein said swellable polymeric
2 coating layer comprises powdered polymeric particles selected from the group consisting of
3 hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose,
4 polyvinylpyrrolidone, polyvinyl alcohol, acrylic acid polymer, methacrylic acid copolymers,
5 ethyl acrylate-methyl methacrylate copolymers, and mixtures thereof.

1 34. The method according to Claim 30, wherein said binder solution is
2 selected from the group consisting of polyvinylpyrrolidone, hydroxypropylmethylcellulose,
3 polyvinyl alcohol, hydroxyethylcellulose, methacrylic acid copolymers, ethylacrylate-
4 methylmethacrylate copolymers, guar gum, arabic gum, xanthan gum, gelatin, pectin, and
5 mixtures thereof.

35. The method according to Claim 30, wherein said step of coating said core with said swellable polymeric coating layer comprises coating said core with a swellable polymeric coating layer not less than 50 μm thick.

36. The method according to Claim 30, wherein said step of coating said core with said swellable polymeric coating layer comprises coating said core with a swellable polymeric coating layer to achieve a core:coating layer ratio of between about 20:1 to about 1:5.

37. A pharmaceutical formulation for the time-specific delivery of a pharmaceutically active agent, said formulation comprising:

(a) a core comprising a capsule containing a liquid form of said pharmaceutically active agent, and

(b) a swellable polymeric coating layer substantially surrounding said core, wherein said swellable polymeric coating layer delays the release of said pharmaceutically active agent from said core for a predetermined period of time dependent upon the thickness of said swellable polymeric coating layer; and wherein said swellable polymeric coating layer is provided by alternately (I) wetting said core with a binder solution, and (ii) coating said core with powdered polymeric particles a sufficient number of times to produce a time-specific dosage formulation having the desired thickness of swellable polymeric coating layer.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 97/01646

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 A61K9/36 A61K9/52 A61K9/66

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 063 014 A (SANKYO CO) 20 October 1982	1,2,4,6, 11,12,14
Y	see abstract see page 5, line 1-10 see page 7, line 4-7 see page 9, line 14-21 see claims 1,2,12 ---	7,18-20, 22,24, 29-31, 33,34,37
X	FR 2 354 094 A (SHIONOGI & CO) 6 January 1978 see page 2, line 29 – page 3, line 9 see page 5, line 8-26 see page 6, line 22-28 see examples 1,6 see claims 12,14 ---	1-5,9-11
		-/-

Further documents are listed in continuation of box C.

Patent-family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"E" earlier document but published on or after the International filing date

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"O" document referring to an oral disclosure, use, exhibition or other means

"&" document member of the same patent family

"P" document published prior to the international filing date but later than the priority date claimed

1

Date of the actual completion of the international search

Date of mailing of the international search report

27 April 1998

07/05/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

La Gaetana, R

INTERNATIONAL SEARCH REPORT

Inter. Serial Application No.

PCT/IB 97/01646

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 3 782 993 A (ROTHGANG G ET AL) 1	7
A	January 1974	
A	see abstract	1-5
A	see column 1, line 36-42	
A	see column 4, line 21-24	
A	see example 1	

Y	US 5 330 759 A (PAGAY SHRIKANT N ET AL)	18-20,
Y	19 July 1994	22, 24,
	see column 2, line 52-65	
Y	see column 3, line 55-61	
Y	see column 5, line 17-22	
Y	see example	
Y	see claim 6	

INTERNATIONAL SEARCH REPORT

information on patent family members

Int'l. Serial Application No.

PCT/IB 97/01646

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0063014 A	20-10-82	JP 1501607 C JP 57171428 A JP 63040131 B US 4533562 A		28-06-89 22-10-82 09-08-88 06-08-85
FR 2354094 A	06-01-78	JP 1046216 C JP 52151717 A JP 55035366 B AT 353416 B CH 630258 A DE 2725390 A GB 1560854 A US 4176175 A		28-05-81 16-12-77 12-09-80 12-11-79 15-06-82 22-12-77 13-02-80 27-11-79
US 3782993 A	01-01-74	AT 307621 B CH 566810 A DE 2057853 A FR 2115947 A GB 1370479 A		15-04-73 30-09-75 15-06-72 07-07-72 16-10-74
US 5330759 A	19-07-94	AT 152618 T AU 672982 B AU 4488893 A CA 2101095 A DE 69310461 D DE 69310461 T EP 0587220 A ES 2104044 T HU 64833 A JP 6157295 A MX 9305108 A		15-05-97 24-10-96 03-03-94 27-02-94 12-06-97 11-12-97 16-03-94 01-10-97 28-03-94 03-06-94 28-02-94